| Literature DB >> 28408742 |
Sven L Klijn1, Mickaël Hiligsmann2, Silvia M A A Evers2, Miguel Román-Rodríguez3, Thys van der Molen4, Job F M van Boven4.
Abstract
With the current wealth of new inhalers available and insurance policy driven inhaler switching, the need for insights in optimal education on inhaler use is more evident than ever. We aimed to systematically review educational inhalation technique interventions, to assess their overall effectiveness, and identify main drivers of success. Medline, Embase and CINAHL databases were searched for randomised controlled trials on educational inhalation technique interventions. Inclusion eligibility, quality appraisal (Cochrane's risk of bias tool) and data extraction were performed by two independent reviewers. Regression analyses were performed to identify characteristics contributing to inhaler technique improvement. Thirty-seven of the 39 interventions included (95%) indicated statistically significant improvement of inhaler technique. However, average follow-up time was relatively short (5 months), 28% lacked clinical relevant endpoints and all lacked cost-effectiveness estimates. Poor initial technique, number of inhalation procedure steps, setting (outpatient clinics performing best), and time elapsed since intervention (all, p < 0.05), were shown to have an impact on effectiveness of the intervention, explaining up to 91% of the effectiveness variation. Other factors, such as disease (asthma vs. chronic obstructive pulmonary disease), education group size (individual vs. group training) and inhaler type (dry powder inhalers vs. pressurised metered dose inhalers) did not play a significant role. Notably, there was a trend (p = 0.06) towards interventions in adults being more effective than those in children and the intervention effect seemed to wane over time. In conclusion, educational interventions to improve inhaler technique are effective on the short-term. Periodical intervention reinforcement and longer follow-up studies, including clinical relevant endpoints and cost-effectiveness, are recommended.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28408742 PMCID: PMC5435089 DOI: 10.1038/s41533-017-0022-1
Source DB: PubMed Journal: NPJ Prim Care Respir Med ISSN: 2055-1010 Impact factor: 2.871
Fig. 1Flow diagram on article inclusion
Fig. 2Quality assessment of included studies. Percentages represent the percentage of included articles having a high risk (black bar), unclear risk (light grey bar) or low risk (medium-grey bar) of bias for each category in the Cochrane Collaboration’s risk of bias assessment tool
Study and intervention characteristics
| FFirst author | Disease | Setting | Sessions | Session length (h:mm) | Delivery | Deliverer | N | Inhaler type | Maximum follow-up (months) | Outcome type | Inhaler technique Improvement | Clinical outcomes | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (%) | (p.p.) | ||||||||||||
| Al-Showair 2007[ | Asthma | Outpatient clinic | 1 | – | Individual | – | 107 | MDI | 1.5 | IFR | – | Peak flow:↑, AQLQ: ↑ | |
| Armour 2013[ | Asthma | Pharmacy | 4 | 00:26 | Individual | Pharmacist | 398 | MDI | 6 | Patients | 50 p.p. | ACQ:≈ | |
| Basheti 2008[ | Asthma | Pharmacy | 4 | 00:03 | Individual | Pharmacist | 97 | DPI | 6 | Steps | 49% | Asthma severity: ↓ | |
| Basheti 2005[ | Asthma | Pharmacy | 1 | 00:08 | Individual | Researcher | 17 | DPI | 0.5 | Steps | 75% | None | |
| Asthma | Pharmacy | 1 | 00:08 | Individual | Researcher | 17 | DPI | 0.5 | Steps | 80% | |||
| Bosnic-Anticevich 2010[ | Both | Pharmacy | 3 | – | Individual | Researcher | 52 | MDI | 4 | Steps | 38% | None | |
| Bynum 2001[ | Asthma* | Outpatient clinic | 1 | 00:15 | Individual | Pharmacist | 49 | MDI | 1 | Steps | 77% | None | |
| Carpenter 2015[ | Asthma* | Outpatient clinic | 1 | 00:03 | Individual | Researcher | 91 | MDI | 1 | Steps | 16% | ACT: ≈ | |
| Chan 2007[ | Asthma* | Outpatient clinic | 5 | – | Individual | Other | 60 | MDI | 12 | Steps | 8% | QOL: ≈, hospitalisations: ≈ | |
| Asthma* | Outpatient clinic | 5 | – | Individual | Other | 60 | DPI | 12 | Steps | 12% | |||
| Chan 2003[ | Asthma* | Outpatient clinic | 4 | – | Individual | Other | 10 | Both | 6 | Steps | – | Peak flow: ↑, QOL: ≈ | |
| Cicutto 2013[ | Asthma* | School | 6 | 00:53 | Group | – | 1316 | – | 12 | Steps | 48% | QOL:↑, Urgent care:↓ | |
| Cordina 2001[ | Asthma | Pharmacy | 1 | – | Individual | – | 152 | – | 12 | Patients | 36 p.p. | QOL: ↑, peak flow: ↑, hospitalisations: ↓ | |
| Crane 2014[ | Asthma | – | 1 | – | Individual | – | 123 | Both | 12 | Patients | 16 p.p. | None | |
| De Blaquiere 1989[ | Both | Outpatient clinic | 1 | 00:17 | Individual | Researcher | 100 | MDI | 2 | Patients | 81 p.p. | Hospitalisations: ≈ | |
| De Oliveira 1999[ | Asthma | Outpatient clinic | 8 | – | – | Researcher | 42 | MDI | 6 | Patients | 73 p.p. | ER visits:↓, symptoms:↓, QOL:↑ | |
| Garcia-Cardenas 2013[ | Asthma | Pharmacy | 3 | – | Individual | Pharmacist | 336 | DPI | 6 | Patients | 56 p.p. | ACQ:↑ | |
| Goodyer 2006[ | Asthma | – | 1 | – | Individual | Pharmacist | 35 | MDI | 0 | Steps | – | None | |
| Asthma | – | 1 | – | Individual | Pharmacist | 34 | MDI | 0 | Steps | – | |||
| Goris 2013[ | COPD | Outpatient clinic | 1 | – | Individual | – | 24 | MDI | 3 | Steps | 100% | QOL:↑, attacks:↓, hospitalisations:≈ | |
| COPD | Outpatient clinic | 1 | – | Individual | – | 110 | DPI | 3 | Steps | 43% | |||
| Hesselink 2004[ | Both | Other | 2 | 00:30 | Individual | Nurse | 276 | – | 24 | Patients | – | QOL: ≈ | |
| Horner 2008[ | Asthma* | School | 16 | 00:15 | Group | Other | 183 | MDI | 1.5 | Steps | 36% | None | |
| Kiser 2012[ | COPD | Hospital | 1 | 00:23 | Individual | Researcher | 99 | MDI | 1.25 | Steps | 29% | None | |
| COPD | Hospital | 1 | 00:23 | Individual | Researcher | 41 | DPI | 1.25 | Steps | 22% | |||
| COPD | Hospital | 1 | 00:23 | Individual | Researcher | 27 | DPI | 1.25 | Steps | 20% | |||
| Kools 2006[ | Asthma | – | 1 | 00:01 | Individual | Researcher | 50 | MDI | 0 | Steps | – | None | |
| Kritikos 2007[ | Asthma | Pharmacy | 1 | 02:30 | Group | Pharmacist | 22 | MDI | 3 | Patients | 73 p.p. | Poor control: ↓, AQOL: ↑ | |
| Asthma | Pharmacy | 1 | 02:30 | Group | Pharmacist | 25 | DPI | 3 | Patients | 79 p.p. | |||
| Asthma | Pharmacy | 1 | 02:30 | Group | Researcher | 20 | MDI | 3 | Patients | 86 p.p. | |||
| Asthma | Pharmacy | 1 | 02:30 | Group | Researcher | 26 | DPI | 3 | Patients | 84 p.p. | |||
| Kumar 2009[ | Both | Hospital | 4 | – | Individual | Pharmacist | 98 | MDI | 2 | Steps | 115% | FEV1:↑ | |
| Both | Hospital | 4 | – | Individual | Pharmacist | 18 | DPI | 2 | Steps | 100% | |||
| Martin 2015[ | Asthma* | Other | 4 | – | Individual | Nurse | 51 | – | 12 | Steps | 50% | Control: ≈ | |
| Asthma* | Other | 4 | – | Individual | Nurse | 50 | – | 12 | Steps | 29% | |||
| Mehuys 2008[ | Asthma | Pharmacy | 3 | – | Individual | Pharmacist | 201 | Both | 6 | Steps | 25% | Nighttime symptoms:↓, ACT:↑ | |
| Mulloy 1996[ | Asthma | Outpatient clinic | 1 | – | Individual | Nurse | 60 | – | 12 | Steps | 20% | Symptoms: ↓, peak flow: ≈ | |
| Patterson 2005[ | Asthma* | School | 8 | – | Group | Nurse | 173 | – | 4 | Patients | 38 p.p. | QOL: ≈ | |
| Perneger 2002[ | Asthma | Hospital | 3 | 01:15 | Group | Other | 131 | – | 6 | Patients | 28 p.p. | QOL: ≈, healthcare utilisation: ≈ | |
| Petkova 2008[ | Asthma | Pharmacy | 5 | – | – | Researcher | 50 | – | 4 | Patients | 14 p.p. | Hospitalisation: ↓, QOL:↑ | |
| Press 2012[ | Both | Hospital | 1 | 00:06 | Individual | Researcher | 50 | MDI | 0 | Patients | 52 p.p. | Health-related events:↓ | |
| Both | Hospital | 1 | 00:06 | Individual | Researcher | 18 | DPI | 0 | Patients | 50 p.p. | |||
| Rahmati 2014[ | Asthma | – | 3 | – | Group | – | 60 | MDI | 1 | Steps | 60% | Peak flow: ↑ | |
| Asthma | – | 3 | – | Group | – | 60 | MDI | 1 | Steps | 90% | |||
| Rootmensen 2008[ | Both | Outpatient clinic | 1 | 00:45 | Individual | Nurse | 191 | – | 6 | Steps | 3% | QOL: ≈, Exacerbations: ↓ | |
| Rydman 1999[ | Asthma | Outpatient clinic | 1 | – | Individual | Researcher | 68 | MDI | 3 | Patients | 36 p.p. | None | |
| Santos 2010[ | Asthma | Outpatient clinic | 2 | 01:00 | Individual | Pharmacist | 28 | MDI | 2 | Steps | 167% | None | |
| Asthma | Outpatient clinic | 2 | 01:00 | Individual | Pharmacist | 28 | DPI | 2 | Steps | 33% | |||
| Tommelein 2014[ | COPD | Pharmacy | 2 | 00:20 | Individual | Pharmacist | 734 | Both | 3 | Steps | 38% | Hospitalisations↓ | |
| Toumas-Shehata 2014[ | Asthma | Pharmacy | 1 | – | Individual | Pharmacist | 101 | DPI | 1 | Steps | 40% | ACQ:↑ | |
| Van der Palen 1997[ | COPD | Outpatient clinic | 1 | 00:45 | Group | Nurse | 70 | Both | 9 | Steps | 26% | None | |
| COPD | Outpatient clinic | 1 | 00:45 | Individual | Other | 73 | Both | 9 | Steps | 18% | |||
| COPD | Other | 1 | 00:45 | Individual | Other | 71 | Both | 9 | Steps | 26% | |||
| Verver 1996[ | Asthma | Other | 1 | – | Individual | Nurse | 48 | DPI | 0.5 | Steps | 9% | Dyspnoea: ↓ | |
| Wilson 1993[ | Asthma | Hospital | 4 | 00:45 | Individual | Nurse | 227 | MDI | 12 | Steps | – | Asthma status: ↑, physical activity: ↑, Acute visits:↓ | |
| Asthma | Hospital | 4 | 01:30 | Group | Nurse | 229 | MDI | 12 | Steps | – | |||
*: children, ↑: increase/improvement, ↓: decrease/worsening, ≈: no difference, Outcome type: mean number or percentage of correct steps (in the table: “Steps”), the percentage of patients who showed a correct technique (in the table: “Patients”), or inhalation flow rate (IFR). Improvement over baseline is either reported as percentage (%) or as percentage points (p.p.)
Linear regression models with improvement over baseline as dependent variable
|
|
| |||||||
|---|---|---|---|---|---|---|---|---|
| β | 95% CI |
| β | 95% CI |
| |||
| min | max | min | max | |||||
| Total number of steps evaluated | 0.065 | 0.027 | 0.104 | 0.002 | ||||
| Intervention setting | ||||||||
| Community pharmacy | [ref] | |||||||
| Hospital | 0.089 | −0.051 | 0.228 | 0.200 | ||||
| Outpatient clinic | 0.149 | 0.024 | 0.274 | 0.022 | ||||
| School | 0.025 | −0.224 | 0.275 | 0.835 | ||||
| Other | −0.004 | −0.172 | 0.164 | 0.958 | ||||
| Age group (adults vs. children) | 0.153 | −0.003 | 0.310 | 0.055 | ||||
| Baseline performance | −2.720 | −3.101 | −2.338 | <0.001 | −1.498 | −1.921 | −1.075 | <0.001 |
| Intervention provider | ||||||||
| Pharmacist | [ref] | |||||||
| Researcher | −0.052 | −0.190 | 0.087 | 0.414 | ||||
| Nurse | −0.224 | −0.450 | 0.001 | 0.051 | ||||
| Other | −0.226 | −0.458 | 0.007 | 0.056 | ||||
| Follow-up time | −0.034 | −0.068 | −0.001 | 0.046 | ||||
Fig. 3Improvement in inhaler technique plotted against baseline performance (a, b), type of intervention (c, d), and patients’ disease background (e, f) with 95% confidence intervals. The left column (a, c, and e) displays results for correct-steps studies, the right column shows results for correct-patients studies